We present a case of fixed drug eruption to propofol following a series of sedations of a patient for a number of day case procedures. The patient experienced oedema and blistering of his penis, increasing in severity and duration following each subsequent exposure. The diagnosis was confirmed by punch biopsy following an intravenous challenge test with propofol. Whilst reports of fixed drug eruptions to anaesthetic induction agents are uncommon, a number of drugs used commonly by anaesthetists are known triggers. We discuss fixed drug eruptions in relation to anaesthetic practice, aiming to raise awareness of this adverse drug reaction.
CASE HISTORY
A 75-year-old male was referred for drug allergy testing following a number of increasingly severe cutaneous reactions following sedation for day case procedures.
The patient's initial adverse reaction occurred after a gastroscopy performed under sedation with midazolam, fentanyl and propofol. Approximately six hours following the procedure, he experienced swelling and oedema of his penis, which resolved over seven days with oral cyproheptadine. Five months later, he experienced a more severe episode of painless penile swelling following repeat gastroscopy, with a similar time delay in symptom development. More prominent penile oedema, accompanied by pain and blisters occurred following removal of a facial skin lesion four months later. This procedure was performed with local anaesthesia and sedation using propofol and fentanyl. A single dose of intravenous cephalothin had been administered. The reaction was once again delayed by six to seven hours. However, on this last occasion the symptoms continued for more than four weeks despite treatment with prednisolone, fexofenadine and topical mometasone. A dermatology opinion was sought and, whilst the examination findings of erythema, severe oedema of the penis and superficial erosions on the glans were consistent with a fixed drug eruption (FDE), a skin biopsy taken on day 14 did not reveal a lichenoid reaction, the feature necessary to confirm this. The symptoms eventually subsided with topical betamethasone. A skin lesion excision was undertaken uneventfully under local anaesthesia, without sedation, a number of weeks later.
Overall, in the six months prior to the initial adverse reaction, the patient had undergone five uneventful endoscopic procedures with the use of midazolam, fentanyl and propofol. In addition, he had a previous history of five general anaesthetics and multiple procedures under local anaesthesia without incident in the preceding five decades. He had no history of drug, latex or food allergy. He had suffered from allergic rhinitis for over 30 years; however, this had improved since moving to a warmer climate. The application of topical agents on the affected area, and the use of any other substances in addition to his regularly prescribed medication before or after these incidents was denied by the patient.
The only agents used prior to all three of the delayed reactions were propofol and fentanyl. Given the patient's concern regarding the increasing severity of these events and his need for repeated endoscopic investigations, intravenous challenge testing was arranged. This was performed following full resolution of symptoms and after two weeks without steroid and antihistamine treatment. The first agent to be investigated was propofol-with full monitoring and safety precautions, 200 mg was administered intravenously in increments maintaining spontaneous ventilation, as would occur with sedation for a colonoscopy. The groin reaction re-curred 12 hours later, in addition to erythematous reactions on his trunk and limbs. Dermatologist examination the next day revealed oedema of the distal penile shaft and violaceous patches on the glans penis with a pseudobullous appearance. Another punch biopsy was taken. A FDE to propofol was confirmed with histological evidence of a lichenoid reaction, with a dense lichenoid inflammatory cell infiltrate into the superficial dermis.
Following this diagnosis, the patient has undergone several uneventful sedations with the use of thiopentone instead of propofol. Fentanyl and midazolam have also been utilised without adverse effect. Written consent was obtained from the patient prior to publication of this report.
DISCUSSION
The case demonstrates a number of classical features of FDE, including morphology, time of onset, recurrence in the same anatomical location and increasing severity of the reaction, on this occasion experienced with each exposure to propofol. FDEs represent one of the most frequently encountered drug eruptions in clinical practice, comprising 9% to 34% of drug eruptions 1 . FDEs are characterised by the appearance of one or multiple well circumscribed, round to ovoid, cutaneous or mucosal macules following exposure to a drug. These lesions recur in the same location after repeated administration and resolve with discontinuation of the medication 2,3 . Symptoms usually begin within 8 to 24 hours of drug administration and may present initially as pruritus, burning pain and erythema 4 . The macules range in colour from red to violaceous and develop into erythematous plaques that characteristically resolve over time to leave residual hyperpigmented areas 5, 6 . Blisters and vesicles may also occur 2 . Recurrence of the eruption at the same site results in erythematous lesions with violaceous centres, resolving with increased pigmentation. With each eruption, the size and number of lesions present may also increase 1, 7 . Although it was not a feature in the case described, a variable refractory period, during which administration of the causative agent will not provoke a FDE, has been reported 2, 8 .
The morphology of FDE lesions may differ amongst individuals. Less common presentations include non-pigmenting and annular lesions; general, bilateral symmetrical, reticular and linear eruptions; urticaria, dermatitis, periorbital hypermelanosis, generalised bullous eruptions (mimicking toxic epidermal necrolysis) and erythema multiforme-like eruptions [1] [2] [3] 7, 9, 10 . This patient demonstrated a differing appearance of the penile reaction with subsequent reactions.
Any area of the skin or mucous membranes may be affected by FDE. The most common sites include the lips, hands, arms, legs, trunk, genitalia and oral mucosa 6, 7, 11 . FDEs of the genitalia are most common in males, with the glans penis most commonly involved, as was the case for this patient [10] [11] [12] [13] . FDEs presented most commonly on the limbs in females in one retrospective analysis 10 . Specific site involvement may be seen more frequently with particular drugs. Naproxen has been associated with FDE of the lips and cotrimoxazole with the glans penis 11 . Areas of previous trauma, such as burns, insect bites, vaccination, venepuncture and healed herpes zoster or simplex lesions, may be prone to involvement 2, 3, 14 .
A variable period of sensitisation to the causative agent precedes the development of FDE, and appears to be shorter in those receiving intermittent, rather than regular, exposure to the drug 8 . Our patient had previously received propofol on multiple occasions without any adverse reaction. However, this was not grounds to exclude it as a possible cause of his drug eruption. Whilst the exact pathophysiology of this reaction has not yet been elucidated, CD8+ T-cells with an effector-memory phenotype accumulate in FDE lesions and persist following resolution 8, 15, 16 . It is postulated that lesional keratinocytes stimulated by the causative drug express ICAM-1, signalling these resident T-cells to release IFN-γ, causing the inflammatory lesion to flare. Migration of IL-10 producing CD4+ T-cells to the lesion may lead to resolution of the eruption 15, 16 . Given the involvement of effector T-cells, FDE could be classified as a type IVc hypersensitivity reaction 2, 17 .
This patient had a number of important measures required for the diagnosis of FDE. Identification of the responsible agent involves obtaining a specific drug history of both new and regular medications and supplements, and the temporal relationship between exposure and lesion presentation 8 . The causative drug is confirmed using provocation testing, which may require patch testing or systemic provocation. Resultant lesion morphology and histology can then be used to clarify the diagnosis of FDE 6 . It is recommended to test more than two weeks following resolution of the lesion, in order to avoid the refractory period.
Patch testing involves topical application of the suspected agent to the site of a previous lesion, and monitoring for flare-up. This test may yield false negative results due to inadequate drug concent-ration, poor skin penetration, metabolites being the causative substance or if the test is undertaken during the refractory period 8 . It is however a useful screening test, particularly in cases of generalised bullous FDE and when multiple drugs are suspected. Systemic provocation remains the gold standard, and may be undertaken with increasing doses of the suspected drug every 24 hours until reactivation of the lesions occurs 2, 8 . Testing options were discussed with this patient. Decisive factors for systemic provocation included that he would need multiple anaesthetics in the future, the inherent difficulties in patch testing on the penis and the increased possibility of false negative reaction with patch testing compared to systemic provocation. In this case, the biopsy 14 days after the third reaction did not contain sufficient diagnostic features to confirm a diagnosis of FDE. A biopsy of the lesion obtained after the provocation testing provided clear histological evidence of FDE.
In the case of propofol, which is utilised with such high frequency in anaesthesia, provocation testing is necessary to confirm or exclude the diagnosis. It is important not to avoid such an integral agent without proven grounds to do so. It is also important to consider that anaesthesia usually requires exposure to a number of agents and, until proven otherwise, the FDE could occur to any substance to which the patient is recurrently exposed. However, this case demonstrates that it is equally important not to miss a rare but distressing diagnosis of FDE, which can often occur after the patient is no longer under anaesthetic care.
The issue of the potential for cross-reactivity with other drugs is an interesting theoretical consideration. Propofol is formulated with a lipid emulsion of similar composition to Intralipid ® (Fresenius SE, Bad Homburg, Hesse, Germany) and, in the absence of further testing, it is impossible to exclude Intralipid causing a similar FDE to propofol 18, 19 . However, each episode of testing involves appreciable risk and discomfort for the patient. The need for Intralipid administration arises only rarely. A history of FDE to propofol would not preclude use of Intralipid in life-threatening circumstances such as severe local anaesthetic toxicity.
The list of drugs associated with FDE continues to grow with the introduction of new agents and the percentage of cases due to certain medications is related to their frequency of use in particular regions 6 . A wide variety of unrelated drugs from a number of pharmacological classes have been implicated in FDE. Antibiotics, particularly trimethoprimsulfamethoxazole, are common culprits. A number of drugs frequently utilised in anaesthesia have been reported to cause FDE (Table 1 ). Of these, the most common triggers are non-steroidal antiinflammatory drugs and paracetamol 6, 7, 20 .
Intravenous anaesthetic agents have also been associated with FDE. Barbiturates have long been a known cause of this drug reaction, in particular phenobarbitone 4 . Three case reports have been published describing FDEs due to the administration of thiopentone, the earliest from 1982. These cases involved the lips and oral mucosa in one patient, the fingers in another and a non-pigmenting FDE involving multiple sites in the third [21] [22] [23] .
Reports of FDE to propofol are uncommon. Subsequent to testing our patient, a confirmed diagnosis of FDE due to propofol was reported and involved a tibial lesion provoked by intradermal testing 24 . Prior to this, a 1988 correspondence outlined a delayed reaction to propofol involving lesions on the neck and scalp occurring on two occasions, the second persisting for longer than the first 25. The diagnosis was not confirmed with testing.
Due to the characteristic delay in appearance of the eruption, we postulate that FDE to propofol occurs more frequently than is currently reported. The reaction may not become apparent until after handover of patient care by the anaesthetist or, in the case of day surgery procedures, discharge home from hospital. Given that patients may be exposed to propofol by a number of different practitioners, in different procedural settings and in multiple institutions, the diagnosis of this already rare adverse drug reaction may be even more easily missed. This article aims to increase awareness and knowledge regarding perioperative FDE, particularly in relation to agents we use on a daily basis. It is important for anaesthetists to have the knowledge to enable them to avoid the recurrence of this preventable condition.
